首页> 外文期刊>Journal of biomedical nanotechnology >Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging
【24h】

Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging

机译:多功能PLGA纳米气泡作为治疗剂:将阿霉素和P-gp siRNA共同递送至人乳腺癌细胞并进行超声细胞成像

获取原文
获取原文并翻译 | 示例
           

摘要

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. One of the effective approaches to overcome MDR is to use nanoparticle-mediated the gene silence of chemotherapeutic export proteins by RNA interference to increase drug accumulation in drug resistant cancer cells. In this work, a new co-delivery system, DOX-PLGA/PEI/P-gp shRNA nanobubbles (NBs) around 327 nm, to overcome doxorubicin (DOX) resistance in MCF-7 human breast cancer was designed and developed. Positively charged polyethylenimine (PEI) were modified onto the surface of DOX-PLGA NBs through DCC/NHS crosslinking, and could efficiently condense P-gp shRNA into DOX-PLGA/PEI NBs at vector/shRNA weight ratios of 70:1 and above. An in vitro release profile demonstrated an efficient DOX release (more than 80%) from DOX-PLGA/PEI NBs at pH 4.4, suggesting a pH-responsive drug release for the multifunctionalized NBs. Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOXresistant and P-glycoprotein (P-gp) over-expression cancer cell line). The IC50 of DOX-PLGA NBs against MCF-7/ADR cells was 2-fold lower than that of free DOX. The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. The cellular uptake mechanism of DOX-PLGA/PEI/P-gp shRNA NBs indicated that the macropinocytosis was one of the pathways for the uptake of NBs by MCF-7/ADR cells, which was also an energy-dependent process. Furthermore, the in vitro cellular ultrasound imaging suggested that the employment of the DOX-PLGA/PEI/P-gp shRNA NBs could efficiently enhance ultrasound imaging of cancer cells. These results demonstrated that the developed DOX-PLGA/PEI/P-gp shRNA NBs is a potential, safe and efficient theranotic agent for cancer therapy and diagnostics.
机译:多药耐药性(MDR)是癌症化学疗法成功的主要障碍。克服MDR的有效方法之一是利用纳米粒子介导的RNA干扰化学疗法输出蛋白的基因沉默,以增加耐药性癌细胞中的药物蓄积。在这项工作中,设计并开发了一种新的共递送系统,即327 nm左右的DOX-PLGA / PEI / P-gp shRNA纳米气泡(NBs),以克服MCF-7人乳腺癌中对阿霉素(DOX)的耐药性。通过DCC / NHS交联将带正电的聚乙烯亚胺(PEI)修饰到DOX-PLGA NBs的表面上,并且可以在载体/ shRNA重量比为70:1或更高的情况下将P-gp shRNA有效地冷凝为DOX-PLGA / PEI NBs。体外释放曲线表明,在pH 4.4时,DOX-PLGA / PEI NB有效释放了DOX(超过80%),表明多功能NB的pH响应药物释放。细胞实验结果进一步表明,DOX-PLGA / PEI / P-gp shRNA NBs可以促进DOX进入细胞的细胞摄取并增强DOX对MCF-7 / ADR细胞的细胞增殖抑制作用(一种抗DOX和P-糖蛋白(P -gp)过度表达癌细胞系)。 DOX-PLGA NBs对MCF-7 / ADR细胞的IC50比游离DOX低2倍。通过荧光显微镜和荧光分光光度法证实了DOX-PLGA / PEI / P-gp shRNA NBs在MCF-7 / ADR细胞中传递的DOX的细胞摄取和核蓄积增加,这可能归因于P-的下调gp并降低DOX的流出。 DOX-PLGA / PEI / P-gp shRNA NBs的细胞摄取机制表明,巨胞饮作用是MCF-7 / ADR细胞摄取NBs的途径之一,也是一个能量依赖的过程。此外,体外细胞超声成像表明,使用DOX-PLGA / PEI / P-gp shRNA NB可以有效增强癌细胞的超声成像。这些结果表明,开发的DOX-PLGA / PEI / P-gp shRNA NBs是用于癌症治疗和诊断的潜在,安全和有效的治疗试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号